▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2095 by analyst upside · 2026-08-13
XENE
Xenon Pharmaceuticals Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+24.6%
implied upside to consensus target
Current Price $65.26
Consensus Target $81.3
Bull Target $100.0
Bear Target $69.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
16
Hold
0
Sell
0
52-Week Low $35.6
52-Week High $72.66
YTD Return +46.7%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $35.6
52-Week High $72.66
Current Price $65.26
Bear Target $69.0
Bull Target $100.0
● Now $65.26 ● Target $81.3
TRADING DATA
Avg Volume 1.4M
YTD Return +46.7%
Analyst Count 19
Consensus Buy
Upside to Target +24.6%
Last Updated 2026-08-13

ANALYST SUMMARY

Xenon Pharmaceuticals Inc. (XENE) is currently trading at $65.26 with a Wall Street consensus price target of $81.3, implying potential upside of 24.6% over the next 12 months. 19 analysts currently cover XENE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $69.0.

XENE operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 46.7% year-to-date and is currently trading near the upper end of its 52-week range of $35.6 – $72.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CAI +21.3%
Caris Life Sciences, Inc.
$6B · P/E 2.3x · Buy
HNGE +21.8%
Hinge Health, Inc.
$7B · P/E 10.8x · Buy
GRFS +37.0%
Grifols, S.A.
$5B · P/E 10.4x · Buy
ACAD +13.8%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy
TGTX +40.8%
TG Therapeutics, Inc.
$8B · P/E 18.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for XENE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-05-27 43% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-05-12 43% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-05-08 Building track record
Needham - Reiterated
Buy → Buy 2026-05-08 20% win rate (5 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-03-16 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-03-10 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-03-10 Building track record
Deutsche Bank - Reiterated
Buy → Buy 2026-03-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
23/30
Consensus clarity
20/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →